Investing

OPEC, Russia and several other producers recently agreed to increase output by 1 million barrels in order to ease oil prices away from 3½-year highs. But many analysts think they will struggle to add that much supply because only a handful of the countries have spare capacity. However, Barclays said the market is underestimating the
0 Comments
Financial markets believe Europe will eventually “accommodate” President Donald Trump on trade, Wall Street’s Art Cashin told CNBC on Monday. “Even if it’s only to a slight degree, the president will step back and claim victory,” said Cashin, director of floor operations for UBS at the New York Stock Exchange. Trump is threatening tariffs on
0 Comments
Biogen shareholders are rejoicing over a clinical trial’s positive results. Shares of the biotech company were up 19.6 percent Friday, a day after Biogen and Tokyo-based Eisai announced positive results from a Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease. The stock move added more than
0 Comments
Even the company dubbed “the Netflix of China” can’t change CNBC’s Jim Cramer’s opinion on Chinese IPOs. “In the midst of the trade tensions with the People’s Republic, China-based companies keep coming public here and their stocks have been roaring,” the “Mad Money” host said Thursday. “Many of these names, though, [are of] dubious quality.”
0 Comments
Walgreens Boots Alliance is not a market innovator. As a consumer retail outlet primarily for the pharmaceutical industry, the firm’s intellectual property holdings are negligible. Where industry leaders have been focused on drug-interaction detection, drug counterfeiting, customizable dosing and the like, Walgreens is dependent on the technology of others. The majority of Walgreens’ pending patents
0 Comments